{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:22:01Z","timestamp":1785770521395,"version":"3.56.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Lung cancer remains a significant medical problem in Asia, and improved treatments are needed for patients diagnosed with non-small cell lung cancer (NSCLC), who are frail with poor performance status or substantial comorbidities. This study aimed to investigate the efficacy and safety of first-line atezolizumab\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . single-agent chemotherapy in the Asian subpopulation in IPSOS trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This exploratory analysis of the Asian subpopulation from the phase 3, global, open-label, randomized controlled IPSOS trial evaluated the efficacy and safety of atezolizumab (1200 mg intravenously every 3 weeks)\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . single-agent chemotherapy (investigator\u2019s choice of vinorelbine or gemcitabine) as first-line treatment in patients with locally advanced or metastatic NSCLC, who were ineligible for platinum-based chemotherapy. The primary outcome was overall survival (OS); other outcomes were progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy patients from China and Vietnam were included. Median OS was 15.8 months in the atezolizumab group\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 12.5 months in the chemotherapy group; unstratified hazard ratio, 0.74 (95% confidence interval 0.41, 1.35). Median PFS was 8.1 months\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 5.4 months, ORR was 27.9%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 7.4%, and median DOR was 18.7 months\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 9.3 months, in the atezolizumab group\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . in the chemotherapy group, respectively. All-grade and grade 3\u20134 treatment-related adverse events (AEs) were less frequent with atezolizumab compared with chemotherapy. Two patients in the atezolizumab group had grade 5 AEs, namely pneumonia and acute left ventricular failure, with the latter considered treatment-related.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Atezolizumab showed encouraging efficacy results and was well tolerated in an Asian subpopulation of patients with NSCLC who were deemed ineligible for standard platinum-based chemotherapy. The findings of this exploratory subpopulation analysis were consistent with those for the global IPSOS population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT03191786.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003796","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:00:10Z","timestamp":1766390410000},"page":"1838-1845","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation"],"prefix":"10.1097","volume":"139","author":[{"given":"Baohui","family":"Han","sequence":"first","affiliation":[{"name":"Department of Respiratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Tuan","family":"Le","sequence":"additional","affiliation":[{"name":"Cho Ray Cancer Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingzhi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejie","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Hospital, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cam Phuong","family":"Pham","sequence":"additional","affiliation":[{"name":"The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, Zhejiang 322000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Centre, Second People\u2019s Hospital of Hunan Province, Changsha, Hunan 410007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Respiratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyou","family":"Hu","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Morris","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Lam","sequence":"additional","affiliation":[{"name":"Genentech Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Graupner","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gitlitz","sequence":"additional","affiliation":[{"name":"Genentech Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elen","family":"Hoglander","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siow Ming","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Oncology, University College London Hospitals NHS Foundation Trust and CRUK Lung Cancer Centre of Excellence, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"R1-20260620","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"R2-20260620","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","article-title":"Global burden and trends of lung cancer incidence and mortality","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J"},{"key":"R3-20260620","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: Profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"R6-20260620","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: Implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J Thorac Oncol"},{"key":"R7-20260620","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01721-2016","article-title":"Comorbidities in the management of patients with lung cancer","volume":"49","author":"Leduc","year":"2017","journal-title":"Eur Respir J"},{"key":"R8-20260620","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-020-00881-7","article-title":"Emerging therapeutic agents for advanced non-small cell lung cancer","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R9-20260620","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1470-2045(12)70412-6","article-title":"First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): A double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"R10-20260620","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-20260620","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R12-20260620","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R13-20260620","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Grant","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R14-20260620","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"38","author":"Hanna","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"R15-20260620","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"R16-20260620","doi-asserted-by":"crossref","first-page":"202","DOI":"10.21037\/tlcr.2018.09.15","article-title":"Immunotherapy for non-small cell lung cancer: From clinical trials to real-world practice","volume":"8","author":"Rashdan","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R17-20260620","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.advms.2021.07.005","article-title":"Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review","volume":"66","author":"Mojsak","year":"2021","journal-title":"Adv Med Sci"},{"key":"R18-20260620","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): A single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R19-20260620","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"R20-20260620","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"R21-20260620","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"R22-20260620","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): A phase 3, global, multicentre, open-label, randomised controlled study","volume":"402","author":"Lee","year":"2023","journal-title":"Lancet"},{"key":"R25-20260620","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: A multicenter international cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:32:15Z","timestamp":1785767535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003796","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"2024-01-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}